These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 18420313)
1. What can HIV vaccine trials teach us about future HIV vaccine dissemination? Newman PA; Duan N; Kakinami L; Roberts K Vaccine; 2008 May; 26(20):2528-36. PubMed ID: 18420313 [TBL] [Abstract][Full Text] [Related]
2. HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. Newman PA; Duan N; Roberts KJ; Seiden D; Rudy ET; Swendeman D; Popova S J Acquir Immune Defic Syndr; 2006 Feb; 41(2):210-7. PubMed ID: 16394854 [TBL] [Abstract][Full Text] [Related]
3. Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand. Celentano DD; Beyrer C; Natpratan C; Eiumtrakul S; Sussman L; Renzullo PO; Khamboonruang C; Nelson KE AIDS; 1995 Sep; 9(9):1079-83. PubMed ID: 8527082 [TBL] [Abstract][Full Text] [Related]
4. HIV vaccine acceptability among women at risk: perceived barriers and facilitators to future HIV vaccine uptake. Rudy ET; Newman PA; Duan N; Kelly EM; Roberts KJ; Seiden DS AIDS Educ Prev; 2005 Jun; 17(3):253-67. PubMed ID: 16006211 [TBL] [Abstract][Full Text] [Related]
5. Posttrial HIV vaccine adoption: concerns, motivators, and intentions among persons at risk for HIV. Newman PA; Duan N; Rudy ET; Roberts KJ; Swendeman D J Acquir Immune Defic Syndr; 2004 Nov; 37(3):1393-403. PubMed ID: 15483469 [TBL] [Abstract][Full Text] [Related]
6. Development of an HIV vaccine attitudes scale to predict HIV vaccine acceptability among vulnerable populations: L.A. VOICES. Lee SJ; Newman PA; Duan N; Cunningham WE Vaccine; 2014 Sep; 32(39):5013-8. PubMed ID: 25045817 [TBL] [Abstract][Full Text] [Related]
7. Willingness to participate in HIV vaccine trials: the impact of trial attributes. Newman PA; Duan N; Lee SJ; Rudy E; Seiden D; Kakinami L; Cunningham W Prev Med; 2007 Jun; 44(6):554-7. PubMed ID: 17275895 [TBL] [Abstract][Full Text] [Related]
8. HIV vaccine acceptability among immigrant Thai residents in Los Angeles: a mixed-method approach. Lee SJ; Brooks RA; Newman PA; Seiden D; Sangthong R; Duan N AIDS Care; 2008 Nov; 20(10):1161-8. PubMed ID: 18608068 [TBL] [Abstract][Full Text] [Related]
9. Differences in HIV vaccine acceptability between genders. Kakinami L; Newman PA; Lee SJ; Duan N AIDS Care; 2008 May; 20(5):542-6. PubMed ID: 18484322 [TBL] [Abstract][Full Text] [Related]
10. Use of conjoint analysis to assess HIV vaccine acceptability: feasibility of an innovation in the assessment of consumer health-care preferences. Lee SJ; Newman PA; Comulada WS; Cunningham WE; Duan N Int J STD AIDS; 2012 Apr; 23(4):235-41. PubMed ID: 22581945 [TBL] [Abstract][Full Text] [Related]
11. Contextualizing willingness to participate: recommendations for engagement, recruitment & enrolment of Kenyan MSM in future HIV prevention trials. Doshi M; Avery L; Kaddu RP; Gichuhi M; Gakii G; du Plessis E; Dutta S; Khan S; Kimani J; Lorway RR BMC Public Health; 2017 May; 17(1):469. PubMed ID: 28521748 [TBL] [Abstract][Full Text] [Related]
12. HIV vaccine trial preparedness among Spanish-speaking Latinos in the US. Brooks RA; Newman PA; Duan N; Ortiz DJ AIDS Care; 2007 Jan; 19(1):52-8. PubMed ID: 17129857 [TBL] [Abstract][Full Text] [Related]
13. Using surrogate vaccines to assess feasibility and acceptability of future HIV vaccine trials in men: a randomised trial in inner-city Johannesburg, South Africa. Chimoyi L; Kamndaya M; Venables E; von Knorring N; Stadler J; MacPhail C; Chersich MF; Rees H; Delany-Moretlwe S BMC Public Health; 2017 Jul; 17(Suppl 3):524. PubMed ID: 28832280 [TBL] [Abstract][Full Text] [Related]
14. HIV vaccine acceptability among communities at risk: the impact of vaccine characteristics. Newman PA; Duan N; Lee SJ; Rudy ET; Seiden DS; Kakinami L; Cunningham WE Vaccine; 2006 Mar; 24(12):2094-101. PubMed ID: 16332402 [TBL] [Abstract][Full Text] [Related]
15. A pilot study on willingness to participate in future preventive HIV vaccine trials. Suhadev M; Nyamathi AM; Swaminathan S; Venkatesan P; Raja Sakthivel M; Shenbagavalli R; Suresh A; Fahey JL Indian J Med Res; 2006 Dec; 124(6):631-40. PubMed ID: 17287550 [TBL] [Abstract][Full Text] [Related]
16. Community heroes or "high-risk" pariahs? Reasons for declining to enroll in an HIV vaccine trial. Newman PA; Daley A; Halpenny R; Loutfy M Vaccine; 2008 Feb; 26(8):1091-7. PubMed ID: 18237829 [TBL] [Abstract][Full Text] [Related]
17. Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand. Newman PA; Roungprakhon S; Tepjan S; Yim S Vaccine; 2010 Jan; 28(4):958-64. PubMed ID: 19925897 [TBL] [Abstract][Full Text] [Related]
18. Young men who have sex with men's awareness, acceptability, and willingness to participate in HIV vaccine trials: Results from a nationwide online pilot study. Connochie D; Tingler RC; Bauermeister JA Vaccine; 2019 Oct; 37(43):6494-6499. PubMed ID: 31522806 [TBL] [Abstract][Full Text] [Related]
19. Willingness to participate in HIV vaccine trials among men who have sex with men in Chennai and Mumbai, India: a social ecological approach. Chakrapani V; Newman PA; Singhal N; Jerajani J; Shunmugam M PLoS One; 2012; 7(12):e51080. PubMed ID: 23226560 [TBL] [Abstract][Full Text] [Related]
20. Willingness to participate in future HIV vaccine trials among men who have sex with men and female sex workers living in Nairobi, Kenya. Mutisya EM; Mutua G; Nyasani D; Nduta H; Kabuti RW; Muturi-Kioi V; Omosa-Manyonyi G; Abaasa A; Lindan K; Price MA; Kimani J; Anzala AO PLoS One; 2020; 15(8):e0238028. PubMed ID: 32834018 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]